Roivant Reports Positive Phase 3 CLARITY Results for Brepocitinib
Roivant said brepocitinib met the primary and all key secondary endpoints in the Phase 3 CLARITY trial in non-infectious uveitis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.